Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Artekin; Eurartekin; Eurartesim; Piperaquine/dihydroartemisinin

Latest Information Update: 12 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chongqing Holley; Medicines for Malaria Venture; sigma-tau SpA; University of Oxford
  • Developer Medicines for Malaria Venture; sigma-tau SpA
  • Class Antimalarials; Artemisinins; Piperazines; Quinolines; Sesquiterpenes
  • Mechanism of Action Free radical stimulants; Hemozoin inhibitors; Protein synthesis inhibitors; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malaria
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malaria

Most Recent Events

  • 12 Oct 2018 No recent reports on development identified - Phase-II for Malaria (In infants) in Congo, Gambia, Mozambique, Burkina Faso, Tanzania (PO, Fast dissolve)
  • 24 Jun 2018 Biomarkers information updated
  • 03 Dec 2015 The Medicines for Malaria Venture announces intention to submit the dispersible paediatric formulation to the EMA in the second quarter of 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top